A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects
-
Published:2024-08
Issue:
Volume:Volume 18
Page:3891-3901
-
ISSN:1177-8881
-
Container-title:Drug Design, Development and Therapy
-
language:en
-
Short-container-title:DDDT
Author:
Yao Feng,
Wang Chenguang,
Ding Jie,
Zhang Qian,
Zheng Liang,
Zhang Qin,
Yang Tianshu,
Zhang Xunmin,
Shan Yong,
Hou Sheng,
Wang Hao,
Zhou Renpeng,
Hu WeiORCID
Publisher
Informa UK Limited